23948sdkhjf

Pfizer’s record year – topped the $100 billion mark

In 2022 Pfizer, as the first pharmaceutical company in history, reached an annual revenue of more than 100 billion dollars, thereby surpassing Johnson & Johnson as the industry’s top selling business.

It was primarily a huge boost from sales of products linked to the covid-19 pandemic – mainly the vaccine Comirnaty and the antiviral drug Paxlovid – that resulted in the company’s historically high revenue, reports Fierce Pharma, which has published a top 20 list of pharma companies by revenue (see below).

Johnson & Johnson had to settle for second place, followed by Roche, MSD and Abbvie, with Swedish-British Astra Zeneca coming in at ninth place.

The top 20 pharma companies by 2022 revenue (2021 revenue)

1. Pfizer $100,33 billion (81,29)

2. Johnson & Johnson $94,94 billion (93,77)

3. Roche $66,26 billion (68,71)

4. MSD (Merck & Co) $59,28 billion (48,70)

5. Abbvie $58,05 billion (56,20)

6. Novartis $50,54 billion (51,63)

7. Bristol Myers Squibb $46,16 billion (46,38)

8. Sanofi $45,22 billion (44,63)

9. AstraZeneca $44,35 billion (37,42)

10. GSK $36,15 billion (46,92)

11. Takeda Pharmaceutical Company $30,00 billion (31,57)

12. Eli Lilly $28,55 billion (28,32)

13. Gilead Sciences $27,28 billion (27,30)

14. Bayer $26,64 billion (27,94)

15. Amgen $26,32 billion (25,98)

16. Boehringer Ingelheim $25.28 billion (24,24)

17. Novo Nordisk $25,00 billion (22,38)

18. Moderna $19,26 billion (18,47)

19. Merck KGaA $19,16 billion (19,11)

20. Biontech 18,20 billion (22,43)

Source: Fierce Pharma

Artikeln är en del av vårt tema om News in English.

Kommentera en artikel
Meddela redaktionen
Utvalda artiklar
Utvalda nyheter från förstasidan
Genmutation som förhindrar smärta kartläggs av forskare
Rockad i ledningen för Kancera
Covidvaccin från Novavax föreslås få fullt godkännande
15 framtidsyrken inom life science: “Huggsexa om kompetens”
Han tar över som ordförande i CTR
Studie: Granatäpplen kan hjälpa till att rena vatten från läkemedel
Andra Nordiska Medier

Nyhetsbrev

Sänd till en kollega

0.094